Jens Holstein net worth and biography

Jens Holstein Biography and Net Worth

Director of Veracyte
Jens Holstein has 25 years of financial and management expertise, spanning an array of global life science businesses.  In 2011, Mr. Holstein was appointed Chief Financial Officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany. Before joining MorphoSys, Mr. Holstein worked at the pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as Regional Chief Financial Officer for the Europe/Middle East Region and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group including Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects and Service business unit of Fresenius, and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry. He holds a Diploma in Business Administration from the University of Münster (Germany).

What is Jens Holstein's net worth?

The estimated net worth of Jens Holstein is at least $34,800.00 as of June 14th, 2022. Mr. Holstein owns 2,000 shares of Veracyte stock worth more than $34,800 as of September 29th. This net worth evaluation does not reflect any other assets that Mr. Holstein may own. Learn More about Jens Holstein's net worth.

How do I contact Jens Holstein?

The corporate mailing address for Mr. Holstein and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected] Learn More on Jens Holstein's contact information.

Has Jens Holstein been buying or selling shares of Veracyte?

Jens Holstein has not been actively trading shares of Veracyte in the last ninety days. Most recently, Jens Holstein sold 8,720 shares of the business's stock in a transaction on Tuesday, June 14th. The shares were sold at an average price of $16.27, for a transaction totalling $141,874.40. Following the completion of the sale, the director now directly owns 2,000 shares of the company's stock, valued at $32,540. Learn More on Jens Holstein's trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Giulia Kennedy (Insider), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, Veracyte insiders bought shares 1 times. They purchased a total of 60,000 shares worth more than $979,800.00. In the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 50,355 shares worth more than $146,383,847.36. The most recent insider tranaction occured on June, 14th when Director Jens Holstein sold 8,720 shares worth more than $141,874.40. Insiders at Veracyte own 2.9 % of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 6/14/2022.

Jens Holstein Insider Trading History at Veracyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2022Sell8,720$16.27$141,874.402,000View SEC Filing Icon  
6/3/2021Buy2,000$35.19$70,380.002,000View SEC Filing Icon  
See Full Table

Jens Holstein Buying and Selling Activity at Veracyte

This chart shows Jens Holstein's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $16.63
Low: $16.32
High: $17.15

50 Day Range

MA: $22.03
Low: $16.58
High: $27.90

2 Week Range

Now: $16.63
Low: $14.85
High: $54.13

Volume

60,797 shs

Average Volume

986,810 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17